Med-El Corporation

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Med-El Corporation sits in the top decile of US sponsors by registered trial count (#987 of 15,742 sponsors by registered trial count).

14 total trials 2 currently recruiting 9 completed top decile by trial count

Med-El Corporation: 14 sponsored US clinical trials, 2 recruiting.

Med-El Corporation sponsors 14 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 9 completed. The most-studied condition in this pipeline is Hearing Loss, Sensorineural, with 2 trials.

Top-decile sponsor footprint

Med-El Corporation ranks in the top decile of sponsors by registered trial count (#987 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 44/100

9 of 11 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

14 total, page 1 of 1

RECRUITING NA

MED-EL Remote Care Multi-Center Feasibility Study

NCT05973669
RECRUITING NA

Single-Sided Deafness and Asymmetric Hearing Loss

NCT04506853
ACTIVE NOT RECRUITING NA

Expanded Indications in the Pediatric BONEBRIDGE Population

NCT05615649
COMPLETED NA

Benefits of Bimodal Streaming With MED-EL Cochlear Implants and Starkey Hearing Aids

NCT07028619
COMPLETED NA

Design Improvements With SONNET 3

NCT06597747
COMPLETED NA

Single-Sided Deafness in the Medicare Population

NCT05250414
TERMINATED NA

BONEBRIDGE Bone Conduction Implant in Adults

NCT03859648
COMPLETED NA

Expanded Indications in the MED-EL Pediatric Cochlear Implant Population

NCT03900897
COMPLETED NA

Expanded Indications in the Adult Cochlear Implant Population

NCT03236909
COMPLETED NA

Electric-Acoustic Stimulation Extended Follow-up Post Approval Study

NCT03031678
COMPLETED

Littlears Auditory Questionnaire: Validation Study in CI Children

NCT00785707
COMPLETED NA

Safety and Efficacy of the Vibrant Soundbridge (VSB) for Mixed and Conductive Hearing Losses

NCT00748540
COMPLETED NA

Safety and Effectiveness of the MED-EL Electric-Acoustic System

NCT00747435
TERMINATED NA

Bilateral Cochlear Implantation in Children With the MED-EL Cochlear Implant

NCT00784043

Therapeutic Areas

Hearing Loss, Sensorineural 2
Hearing Loss 2
Cochlear Implant Recipients 1
Hearing Loss, Mixed 1
Hearing Loss, Conductive 1
Cochlear Implant 1
Hearing Disorders 1
Cochlear Implants 1
Hearing Loss, Unilateral 1

What is open in the Med-El Corporation pipeline

2 recruiting of 14 indexed (14% open); 9 completed (64%).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Hearing Loss, Sensorineural (2 trials), 8 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Med-El Corporation: open-pipeline peers nationwide

Peers matched on 14 registered trials and 14% open enrollment, not the therapeutic-area sidebar.

Med-El Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 01020304050 0%5%10%15%20% Total trials Recruiting share Med-El Corporation3-C Institute for Social DevelopmentAbbott Medical OpticsAbbott RDx CardiometabolicAcceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USAAcademic and Community Cancer Research UnitedAdaptive BiotechnologiesAgelessRxAlaska Blind Child Discovery
Med-El Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Med-El Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 14 trials (± recruiting share)

Sponsors near 14% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Med-El Corporation page

14 registered trials is a research-attention snapshot, not an endorsement of Med-El Corporation or any single study.

  • 2 of Med-El Corporation's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Hearing Loss, Sensorineural is the condition Med-El Corporation studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hearing Loss, Sensorineural trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Med-El Corporation pipeline card: 14 registered trials from official public datasets.Report a data error.